The AHSN Network has supported many innovators to help advance our health and care system. Find out more about successful innovations supported by the NHS.
Syrona is a digital health platform providing support to women through our app SORA for employee benefits supporting women through various health transitions during their careers such as Endometriosis, PCOS and menopause.http://syronahealth.com
Dermicus is an NHSX DTAC approved specialist teledermatology platform for the remote diagnosis and management of skin cancer, general skin lesions and wounds. Dermicus is securely integrated into electronic patient records systems in primary and secondary care using the NHS IM1 pairing, FHIR and other integration standards. All patient data and information security meet the highest standards required by the NHS, validated by an ISO 27001 accreditation.
COVID-19 has generated a significant backlog of elective patients that need appointments generated as quickly as possible. Trusts are keen to avoid hiring more staff to solve the problem and are looking to digital workers instead. Bots can assist with the recovery of elective care in a predictable and consistent way. For example, Automation Anywhere's Robotic Interface (AARI) can be used to extract patient details from referral systems, before cross-checking details against SPINE. Once validated, bookings can be made within the PAS terminal. All bookings and referrals are triaged in e-RS (e-Referral Service) with the outcome.
Aparito is a med-tech company specialising in capturing patient generated data and digital endpoints remotely, with a specific expertise in decentralised/ hybrid studies. As a leading provider of mHealth and remote patient monitoring technology with specialist regulatory and clinical expertise, with our technology it is possible to capture Real-World Patient Data through a variety of sources. These include eQuestionnaires, videos, voice, pictures and wearable device integration.
The ‘Whose Shoes?®’ approach, created by Gill Phillips, is an engaging approach to coproduction, used in over 80 NHS trusts, universities and more.
MetaGuideX is a diagnostic research company that has developed an accurate, fast, non-invasive diagnostic for predicting metastasis (spread of cancer cells) with high specificity and sensitivity. With this tool, they aim to redefine the cancer care pathway. The tool is designed to be used alongside existing standard investigation methods to reduce the need for lymph node biopsies, saving the patient from unneeded procedures and the NHS money.
Early detection of melanoma is crucial for disease prognosis and survival rate. The Primary Care Innovations Programme has partnered with Gnosco to implement and evaluate the Dermicus teledermatology Platform across all GP locations on the Isle of Wight.
The SNAPe-i is easily fitted onto all conventional surgical masks, the patient then wears the mask and aligns the SNAPe-i with their nostril. This enables the surgeon to perform a nasendoscopy while minimising their risk of infections should the patient cough or splutter.
Multi Disciplinary Team Meetings (MDTM) are a central part of the cancer pathway but are becoming increasingly resource-intensive and face many challenges.In your trust these meetings might currently be face to face, held weekly in meeting rooms. Chairing, attending and managing MDTMs may become increasingly challenging: the pressure of excessive case-loads, lack of time to discuss patients and an increase in costs, may result in insufficient attendance at your MDTM and an inability to securely access appropriate data. Patient information is not always available to the MDTM, resulting in a delay in or poor decision-making.
An innovative cancer diagnostic device developed by Manchester-based Zilico helps to improve accuracy in detecting cervical disease.
The Oxford AHSN Accelerator programme, in collaboration with BioCity and regional partners from the NHS, industry and research within the Thames Valley, offers a launchpad for entrepreneurs and their ventures to move from idea to market. CanSense and Dravya Discovery won a place on the intensive eight-week programme and pitched to investors on the final day of the Accelerator programme in November 2019.
Physiomics has developed a proprietary modelaided simulation of tumours, Virtual Tumour™, to help pharmaceutical companies improve the success rate of drug development.
